At a glance
- Originator Essential Therapeutics [CEASED]
- Class
- Mechanism of Action Membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Candidiasis
Most Recent Events
- 05 Oct 2004 Discontinued - Preclinical for Candidiasis in USA (unspecified route)
- 15 Dec 2003 No development reported - Preclinical for Candidiasis in USA (unspecified route)
- 26 Sep 2000 Preclinical development for Candidiasis in USA (Unknown route)